# Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis

> **NCT02116556** · PHASE2 · UNKNOWN · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 29 (actual)

## Conditions studied

- Alcoholic Hepatitis

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT02116556
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2016-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02116556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02116556, "Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02116556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*